What Should a Woman’s Testosterone Level Be on Pellets?

There is no universally agreed-upon testosterone target for women using subcutaneous pellets, because no major medical society has endorsed pellet-delivered testosterone for women or published official dosing guidelines for it. In practice, many pellet providers aim for trough levels somewhere in the upper half of the normal female range, which works out to roughly 30 to 50 ng/dL. But the reality of pellet therapy is more complicated than a single target number, and the levels women actually reach on pellets frequently exceed normal female physiology by a wide margin.

What Normal Female Testosterone Looks Like

Before talking about pellet targets, it helps to know where women’s testosterone sits without any supplementation. A healthy premenopausal woman at age 30 has a total testosterone range of roughly 15 to 46 ng/dL, with free testosterone between about 1.2 and 6.4 pg/mL.¹ A broader age range of premenopausal women (20 to 49) shows total testosterone from about 13 to 56 ng/dL when measured with high-accuracy mass spectrometry methods.² After menopause, the range dips slightly, to roughly 9 to 52 ng/dL for women between 50 and 80.²

Women produce only about 5% as much testosterone as men of the same age.³ That means the total amount is small, and small absolute shifts can represent a large percentage change. A jump from 30 ng/dL to 90 ng/dL might barely register on a chart scaled for men, but it represents tripling a woman’s testosterone.

What Pellets Actually Do to Your Levels

Subcutaneous testosterone pellets are compounded cylinders of crystalline testosterone inserted under the skin, usually in the hip or buttock area. They dissolve slowly and release testosterone over about four to six months. That slow-release profile is a selling point, but it creates a distinctive pharmacokinetic pattern that matters a lot for understanding your bloodwork.

Pellets produce a steep early peak that is often well above normal female range. A review of pellet safety found that early peaks commonly reach above 100 to 250 ng/dL, with wide differences from person to person.⁴ One study measuring women at four weeks after insertion found mean testosterone levels around 299 ng/dL, which is roughly six to ten times the upper limit of normal female testosterone. Even when their symptoms returned (a sign the pellet was wearing off), their mean testosterone was still about 171 ng/dL.⁵ These are not fringe findings from unusual dosing. The study examined women receiving standard-of-care pellet therapy from experienced providers.

A separate long-term study using 75 mg and 100 mg pellets found mean trough levels settling around 67 to 68 ng/dL for both dose groups.⁶ These trough values, measured when the pellet was at its lowest output, are still above what most reference labs consider the top of normal for women. Peak levels observed within the first six months ran considerably higher.

The variability between individuals is striking. Even when women received identical pellet doses, week-four testosterone levels varied by over 40% from person to person, and there was also meaningful variation across different times of day within the same woman.⁵ So two women getting the same pellet dose on the same day can end up at very different testosterone levels. Your body’s rate of pellet absorption, blood flow to the insertion site, body composition, and metabolic factors all play a role.

Why There Is No Official Target

The core reason no official target exists is that the major medical organizations have not endorsed testosterone pellets for women in the first place. The American College of Obstetricians and Gynecologists has stated that compounded bioidentical hormone therapy, which includes pellets, should not be prescribed routinely when FDA-approved formulations exist, and that evidence supporting the safety and effectiveness claims of compounded products is lacking.⁷ No FDA-approved testosterone product currently exists for women in the United States. The patches and gels that have been studied in clinical trials for women’s sexual health are transdermal preparations, not pellets.

Researchers working on testosterone for women’s sexual health have focused on keeping levels within the normal physiologic range. The best-studied dose for postmenopausal women with low desire is a transdermal testosterone patch delivering 300 micrograms per day, which has shown improvements in desire and sexual satisfaction in large randomized trials.⁸ These patches are calibrated to produce testosterone levels within the normal female range, not above it. The clinical trials that form the evidence base for treating low desire in women used physiologic dosing. The supraphysiologic levels commonly seen with pellets have not been studied in the same rigorous way for the same indications.

So when a pellet provider tells you their target is, say, 80 or 100 ng/dL, or even 150 or 200 ng/dL, you are essentially in clinician-by-clinician judgment territory rather than guideline-based medicine. Some practitioners argue that women feel better at levels above the traditional reference range and that clinical symptoms matter more than lab numbers. Others counter that the evidence base for supraphysiologic dosing in women is thin and that the safety profile beyond a few years is largely unknown.

How the Lab Test Itself Can Mislead You

This is an underappreciated wrinkle. The type of assay your lab uses to measure testosterone significantly affects the number you get, and the lower a woman’s testosterone (compared with male ranges), the bigger the error. Standard immunoassay methods, which are what most commercial labs use, have been shown to overestimate testosterone in women’s blood samples by an average of about 46% compared with the gold-standard method (isotope-dilution gas chromatography-mass spectrometry).⁹ Some individual immunoassay platforms overshoot by even more. A comparison of five different immunoassays found that all five overestimated testosterone in women and children, and none were sufficiently reliable at low concentrations.¹⁰

Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the preferred method for accurately measuring testosterone at the low levels found in women.¹¹ If your provider is using a standard immunoassay and telling you your testosterone is 80 ng/dL, the true value could be meaningfully lower, or the reverse could be true with a different assay platform. This matters because if you are trying to track whether you are in a certain range, an inaccurate assay means you might be making dose adjustments based on a wrong number. Ask your clinic which assay method the lab uses. If the answer is a standard immunoassay, take the absolute number with a grain of salt and focus more on trends over time and symptom response.

Side Effects Linked to Supraphysiologic Levels

The most common side effects of testosterone pellets in women are androgenic: acne, oily skin, and increased body or facial hair growth. These tend to be more frequent and more pronounced at higher testosterone levels. At the supraphysiologic concentrations that pellets often produce, more serious effects become possible, including voice deepening, mood changes, and weight gain.¹² Voice deepening is worth special attention because it can be irreversible. Once the vocal cords thicken under androgen influence, lowering the testosterone later does not always bring the voice back.

Randomized controlled trials and meta-analyses of testosterone therapy for low desire in postmenopausal women have generally found a reassuring short-term safety profile when physiologic doses are used, with side effects mostly limited to mild androgenic symptoms and serious adverse events reported infrequently.¹³ The key phrase is “physiologic doses.” Most of the safety data comes from transdermal patches and creams delivering testosterone within normal female range. The safety profile of the supraphysiologic levels produced by pellets simply does not have the same depth of evidence behind it.

One important practical distinction with pellets: once a pellet is inserted, you cannot easily adjust the dose. If your levels spike too high and you develop unwanted symptoms, you are mostly stuck waiting for the pellet to dissolve, which takes months. A cream or patch can be stopped immediately. This irreversibility is one reason medical organizations have been cautious about pellets relative to other delivery methods.

What About Long-Term Risks and Benefits

The honest answer is that long-term data on testosterone pellets in women is sparse. Most studies cover months to a few years, not decades. One prospective observational study found that women treated with subcutaneous testosterone (with or without an aromatase inhibitor) had a reduced incidence of breast cancer compared with expected population rates.¹⁴ That is a provocative finding, but it is a single observational study with inherent selection biases, not a randomized trial. It is not strong enough evidence to claim that pellets protect against breast cancer.

Cardiovascular risk is another open question. The long-term study of 75 mg and 100 mg pellets found no significant changes in hematocrit (a measure of red blood cell concentration that can increase stroke and clot risk when elevated) or systolic blood pressure in either dose group over the treatment period.⁶ That is reassuring, but absence of a signal in a single study does not equal proof of safety. No large-scale randomized trial has followed women on testosterone pellets long enough to know the full cardiovascular picture.

Testosterone therapy research in women has focused overwhelmingly on sexual desire, and that evidence base is concentrated on transdermal delivery at physiologic doses.¹⁵ There is no consensus on what constitutes testosterone deficiency in women, and no formally recognized “androgen deficiency” diagnosis for women exists the way it does for men.¹⁶ This gap means the entire framework of pellet dosing in women is extrapolated from limited evidence rather than built on an established diagnostic category.

Why the Same Dose Affects Women So Differently

The dramatic person-to-person variability in testosterone levels on identical pellet doses has biological roots beyond just absorption rate. One factor is the androgen receptor itself. The androgen receptor gene contains a repeating DNA segment whose length varies among individuals and across ethnic groups. Shorter versions of this repeat are associated with a more active receptor, meaning the same circulating testosterone level produces a stronger biological signal. The relative receptor activity, from most to least active, follows a pattern: Afro-Caribbean, Caucasian, Hispanic, and Thai populations.¹⁷

This means two women could have the same testosterone level on a blood test but experience quite different effects. A woman with a shorter androgen receptor repeat may develop androgenic side effects at a testosterone level that another woman tolerates easily. Conversely, a woman with a longer repeat might need a higher circulating level to feel any benefit. This genetic dimension is essentially never tested in clinical practice, but it helps explain why cookbook dosing based on a single target number fails so many women. Symptoms and side effects are a better guide than lab numbers alone.

Sex hormone-binding globulin (SHBG) adds another layer. SHBG is a protein in the blood that binds testosterone and makes it unavailable to tissues. Women with high SHBG levels have less free testosterone available, even if their total testosterone looks adequate on a lab report. Oral estrogen, for example, raises SHBG significantly, which can offset some of the testosterone a pellet delivers. Body weight, thyroid function, and liver health also influence SHBG. This is why many providers check free testosterone or bioavailable testosterone alongside total testosterone when monitoring pellet therapy.

Continuation Rates and the Practical Experience

Despite the medical controversies, pellet therapy is popular and growing. A large dataset covering over 1.2 million subcutaneous implant procedures across seven years reported that 85% of the procedures were performed in women, and the overall complication rate was below 1%. After a second insertion, 93% of patients continued therapy.¹⁸ That continuation rate suggests that most women who try pellets feel enough benefit to keep going. The complications that do occur are mostly local, including minor bleeding, infection at the insertion site, and occasional pellet extrusion.

High continuation rates do not prove medical safety or optimal dosing. They reflect patient satisfaction, which is important but is a different thing. A woman might feel dramatically better on a supraphysiologic testosterone level and choose to continue without knowing what her risk profile looks like ten or twenty years down the road. That is a personal tradeoff every patient should understand clearly before committing to repeated insertions.

Practical Monitoring If You Are on Pellets

If you are already using testosterone pellets or considering them, getting useful information from your lab work requires some awareness of timing and test quality. Most providers will check your testosterone level at two key time points: near the peak (around four to six weeks after insertion) and near the trough (just before your next insertion, typically at three to five months). The peak tells you how high your levels climbed; the trough tells you where they settle.

Given the assay accuracy issues discussed earlier, request that your lab use LC-MS/MS for testosterone measurement rather than a standard immunoassay. Not every lab offers this, but large reference labs typically do. If your clinic’s in-house lab uses immunoassay, you may need to request a send-out to a reference laboratory. The difference in accuracy at female-range testosterone concentrations is not subtle.

Beyond bloodwork, track your own symptoms between visits. Increased acne, oily skin, facial hair, scalp hair thinning, irritability, and any change in your voice are all signals that your testosterone may be running too high. A change in voice pitch, even a subtle one, should prompt a conversation with your provider about whether to switch to a lower-dose pellet or a different delivery method entirely. These androgenic symptoms are your body’s real-time feedback about how much androgen effect it is experiencing, and they can be more telling than a lab number filtered through an imprecise assay.

The Compounding Factor

Testosterone pellets for women are compounded products, not FDA-approved drugs. Compounding pharmacies prepare them individually or in small batches, and they are not subject to the same manufacturing oversight, consistency testing, or labeling requirements as FDA-approved medications. ACOG has noted that many compounding pharmacies market these products with language implying they are natural and therefore safer, but that evidence supporting those claims is lacking.⁷

The practical implication is that pellet quality can vary between compounding pharmacies and even between batches from the same pharmacy. A 75 mg pellet from one compounder may not dissolve at exactly the same rate as a 75 mg pellet from another. This adds yet another layer of variability on top of the biological differences between individual women. If you switch compounding pharmacies, treat it as a potential dose change and monitor accordingly. Some providers work with a single compounding pharmacy over time specifically to reduce this batch-to-batch variability.

None of this means pellets are inherently dangerous or that every woman on them is taking a reckless risk. But it does mean that the confident-sounding target numbers you might encounter online or from a pellet clinic (“we aim for 80 to 120 ng/dL” or “your sweet spot is around 150 ng/dL”) are not backed by the kind of rigorous clinical trial evidence that supports, say, a statin dose recommendation or an insulin target. They are clinical opinions based on practitioner experience and patient feedback, which is a legitimate input but a weaker form of evidence than most women realize.

1
PubMed. Testosterone reference ranges in normally cycling healthy premenopausal women
2
The Journal of Clinical Endocrinology & Metabolism. Age-Specific Reference Ranges for Serum Testosterone and Androstenedione Concentrations in Women Measured by Liquid Chromatography-Tandem Mass Spectrometry
3
PubMed. Reference intervals for testosterone, androstenedione and SHBG levels in healthy females and males from birth until old age
4
PubMed Central. Testosterone Pellets in Women: Revisiting Safety and Clinical Outcomes
5
PubMed. Testosterone implants in women: pharmacological dosing for a physiologic effect
6
PubMed Central. Long-term testosterone pellet insertion in women with low libido shows no evidence of erythrocytosis and a minimal side effect profile
7
Obstetrics & Gynecology. Compounded Bioidentical Menopausal Hormone Therapy: ACOG Clinical Consensus No. 6
8
PubMed. Testosterone therapy for female sexual dysfunction: a systematic review of the literature demonstrating outcomes in premenopausal and postmenopausal women
9
PubMed. Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children
10
PubMed. Low serum testosterone assayed by liquid chromatography-tandem mass spectrometry. Comparison with five immunoassay techniques
11
PubMed. Comparing immunoassay and mass spectrometry techniques for salivary sex hormone analysis
12
Rev. Assoc. Med. Bras. Compounded hormonal pellets: a critical review of current evidence and risks
13
Inquisiva Open. Serious Adverse Events Following Subcutaneous Testosterone Pellet Therapy in Women: A Structured Narrative Review of Published Case Reports
14
PubMed. Reduced breast cancer incidence in women treated with subcutaneous testosterone, or testosterone with anastrozole: a prospective, observational study
15
Trends in Endocrinology & Metabolism. Androgens in women
16
PubMed. Testosterone for the Treatment of Hypoactive Sexual Desire Disorder in Perimenopausal and Postmenopausal Women
17
PubMed Central. Ethnic Variation in Allele Distribution of the Androgen Receptor (AR) (CAG)n Repeat
18
Therapeutic Advances in Endocrinology and Metabolism. Low complication rates of testosterone and estradiol implants for androgen and estrogen replacement therapy in over 1 million procedures